Food, Global Health 2 min

Diabetes and obesity: the disappearance of a glucose detector in the abdomen

PRESS RELEASE - The continuous detection of blood glucose is vital for anticipating hypoglycaemia and limiting hyperglycaemia, both of which are harmful, particularly in diabetes. Two sensors exist in mammals; one in the brain and the other in the abdomen. Thanks to an innovative imaging methodology, INRAE and the University of Adelaide (Australia) have, for the first time, succeeded in quantifying the activity of the abdominal glucose sensor in animals and humans. Their results, published in a series of three articles, demonstrate the disappearance of this sensor in obese patients, and open new therapeutic perspectives to prevent the harmful consequences of obesity eliciting this sensor’s restoration.

Published on 26 October 2020

illustration Diabetes and obesity: the disappearance of a glucose detector in the abdomen
© INRAE - Christophe Maitre

The detection of blood glucose is crucial. The first sensor is found in the hypothalamus in the brain, and mainly detects hypoglycaemia, while the second is in the abdomen at the level of the portal vein which drains blood from the digestive tract. Its principal role is to detect hyperglycaemia. However, the characteristics and variations of this sensor, particularly in obese or diabetic patients, were hitherto unknown.

To enable direct study of this sensor, the scientists synthesised a radio-labelled probe binding to it. They monitored the level of probe binding to the sensor using an innovative molecular imaging methodology (PET-CT – see insert). This was able to localise, quantify and measure the activity of the glucose detection sensor in the portal veins of miniature pigs before and after weight gain, up to the stage of pre-diabetes. In animals that were not overweight, the researchers were able to determine that the sensor mechanism extended over a short distance at entrance to the liver but not throughout the portal vein. In obese animals, the sensor had disappeared, thus preventing the detection of glucose in the abdomen. These findings were confirmed by recording the nervous signal arising from the same sensor and finding that the signal sent to the brain was indeed suppressed.

Disappearance of the portal sensor during weight gain removes crucial information for the brain which can no longer correctly evaluate blood glucose levels. This disappearance is probably implicated in the events that transform obesity into type II diabetes. However, its restoration appears to be possible insofar as the imaging methodology developed here enables the rapid and non-invasive monitoring of this sensor, which is a significant advance in personalised medicine. These findings offer new prospects for the prevention and treatment of obesity and diabetes.

PET-CT imagery

To detect glucose, the portal vein sensor uses receptors that detect a hormone (glucagon-like peptide 1). These receptors are also sensitive to other molecules, some of which are notably used to treat diabetes. It was by using a labelled probe (i.e. detectable using imaging technologies) binding to these receptors that the scientists were able to localise and measure the activity of the glucose sensor. During the same examination, hybrid PET-CT imaging was able to monitor the binding of this labelled probe proportionally to the density of receptors (PET image) in the patient’s body (CT image).


Figure: PET-CT image of the activity of portal vein sensors (in colour) in an animal model. Lower right: three-dimensional representation of the portal vein in the same animal. © INRAE / Charles-Henri Malbert


Charles-Henri Malbert, Alain Chauvin, Michael Horowitz, Karen L Jones, Glucose-sensing mediated by portal GLP-1 receptor is markedly impaired in insulin-resistant obese animals. Diabetes, Diabetes 2020 Oct,

Jones KL, Huynh LQ, Hatzinikolas S, Rigda RS, Phillips LK, Pham HT, Marathe CS, Wu T, Malbert CH, Stevens JE, Lange K, Rayner CK, Horowitz M. Exenatide once weekly slows gastric emptying of solids and liquids in healthy, overweight people at steady-state concentration. Diabetes Obes Metab. 2020, 22: 788-797 doi:


Learn more

Food, Global Health

Artificial sweeteners: certain adverse metabolic effects revealed in a preclinical model

PRESS RELEASE- INRA researchers, in collaboration with the University of Adelaide, Australia, studied the effects that a widely used artificial sweetener blend, i.e. acesulfame K-sucralose, has on metabolism. For the first time, they revealed – in animals – an increase in glucose absorption, particularly in the brain and fatty tissues, indicating certain undesirable effects on metabolism and insulin sensitivity. These results were published in the 24 July 2019 edition of the European Journal of Nuclear Medicine and Molecular Imaging.

12 December 2019

Food, Global Health

New prebiotics: benefits without the downsides?

PRESS RELEASE - Prebiotics are currently a preferred treatment for certain metabolic disorders, as they can restore the balance of dysfunctional gut microbiota, and improve the body’s metabolism. However, these substances have to be used at high doses, which can result in patients experiencing bloating and flatulence. A research group led by Matteo Serino, Inserm researcher at the Digestive Health Research Institute (Inserm/INRA/ENVT/UT3 Paul Sabatier), has recently shown three plant extracts to have prebiotic effects in obese/diabetic mice, with a shorter duration of treatment and at lower doses to the prebiotics currently in use. For Matteo Serino, this raises the question: do we need to reconsider the protocol for prebiotic administration? These results have been published in Molecular Nutrition & Food Research.

12 December 2019

Food, Global Health

Statins could help restore a healthy gut microbiome in obese people

A cohort study of 900 subjects with varying obesity levels published in Nature on 6 May 2020 has confirmed that obese people are more likely than others to suffer from a disturbed microbiome profile associated with systemic inflammation. But the study found this was not the case in members of this group who were taking statins, suggesting that these cholesterol-reducing drugs could have a beneficial effect on the microbiome. Further investigations are now in progress to see if a causal relationship can be established.

28 May 2020